Cogent Biosciences (COGT) Cash & Equivalents (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Cash & Equivalents data on file, last reported at $241.2 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 91.43% year-over-year to $241.2 million in Q1 2026; TTM through Mar 2026 was $241.2 million, a 91.43% increase from a year earlier, with the FY2025 full-year figure at $312.0 million, up 217.84% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $241.2 million, down from $312.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for COGT reached as high as $325.6 million in Q2 2022 and fell as low as $53.2 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $161.4 million across 5 years, with a median of $139.9 million in 2022.
• Across the five-year window, Cash & Equivalents sank 61.95% in 2023 and soared 217.84% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $139.9 million in 2022, then sank by 61.95% to $53.2 million in 2023, then surged by 84.42% to $98.2 million in 2024, then surged by 217.84% to $312.0 million in 2025, then fell by 22.69% to $241.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $241.2 million in Q1 2026, $312.0 million in Q4 2025, and $125.3 million in Q3 2025.